This product can inhibit the synthesis of prostaglandins and has antipyretic, analgesic and anti-inflammatory effects.

It competes with p-aminobenzoic acid for dihydrofolate synthase, inhibiting bacterial dihydrofolate synthesis; when used in combination with trimethoprim and sulfadiazine, it enhances the antibacterial effect and reduces drug-resistant strains.

It competes with p-aminobenzoic acid for dihydrofolate synthase and inhibits bacterial dihydrofolate synthesis; when used in combination with trimethoprim and sulfamethoxazole, it enhances the antibacterial effect and reduces drug-resistant strains.

By inhibiting bacterial dihydrofolate reductase, it prevents the reduction of dihydrofolate to tetrahydrofolate; when used in combination with sulfamethoxazole and sulfadiazine, it enhances the antibacterial effect and reduces drug-resistant strains.

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial activity against the following bacteria in vitro: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes and other Enterobacter species, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. Norfloxacin also has antibacterial activity against multi-drug resistant bacteria in vitro. It also has good antibacterial effects on penicillin-resistant Neisseria gonorrhoeae, Haemophilus influenzae and Moraxella catarrhalis. Norfloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

It has the function of increasing the activity of digestive enzymes. It can increase the activity of pepsin and pancreatic lipase. It has the function of affecting intestinal motility. It can increase the propulsion rate of carbon powder in the small intestine of mice; it can antagonize the inhibitory effect of atropine sulfate on small intestinal motility.

It has the function of increasing the activity of digestive enzymes. It can increase the activity of pepsin and pancreatic lipase. It has the function of affecting intestinal motility. It can increase the propulsion rate of carbon powder in the small intestine of mice; it can antagonize the inhibitory effect of atropine sulfate on small intestinal motility.

It has the function of increasing the activity of digestive enzymes. It can increase the activity of pepsin and pancreatic lipase. It has the function of affecting intestinal motility. It can increase the propulsion rate of carbon powder in the small intestine of mice; it can antagonize the inhibitory effect of atropine sulfate on small intestinal motility.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Rifampicin has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus aureus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis.